The RS makes no sense to me. The current share structure
The RS makes no sense to me. The current share structure doesn't call for it. Not at their current burn rate, and not with their current loan.
There are only 2 reasons why I can think of that they would do an R/S and neither of them is good. I disagree 100% with the sending a message to the lender. If I was the lender and they did an RS I wouldn't care. I have sold the shares they currently diluted for me, and what do I care about the next go round when I dilute again whether its before or after the split? I would still get my shares and my money, but the ownership would be screwed.
the Nasdaq move I find highly dubious as well. Without Revenue to back up the reverse split, its just going to sink again, plus it will have the stigma of having done a reverse split, which will drive investors away not draw in new ones.
the only reasons I can think of to do it are to screw over the retail investors so big money interests can take over percentage wise, OR they know they have some massive expenses coming up on their future tests. Perhaps Sheba has informed them they are not going to get those huge discounts they are getting now when it comes to the second phase of trials, and they are looking at many millions in expenses for testing, and they don't have enough shares to sell now to new money. which would mean severe dilution.
Neither one of those scenarios is good. The Nasdaq thing everyone is pushing seems unlikely to me. Not without something else to give it a kick in the pants.
I don't see any good outcome as being likely from a RS.
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...
Continue Reading
Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...
Continue Reading
Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...
Continue Reading
A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...
Continue Reading
Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...
Continue Reading
Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...
Continue Reading
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Franklin Universal Trust's Distribution Sources In the investment landscape, knowing the sources of distributions can significantly inform investors about the health of their investments. Franklin Universal Trust (NYSE: FT) recently provided an update on its distribution sources, which is vital for shareholders seeking to gauge the Fund’s performance....
Continue Reading
Bitcoin's been stuck in neutral territory lately, trading flat as of Monday with a mild dip in volatility due to holiday-driven thin liquidity. It pushed up to $70,060 but faced serious resistance, retreating back into the $68,000 zone where it seems to be camping out. Volume? Yeah, that dropped a cool 17% from yesterday's action—so you know how traders get restless...
Continue Reading
Anticipated Growth in the Automotive Wiper Blade Market The global automotive wiper blade market is poised for significant growth in the coming years. Projections estimate that the market value will climb to USD 11.5 billion by 2034, up from USD 6 billion in 2024. This increase signifies a compound annual growth rate (CAGR) of 6.8%. Key drivers of this growth include...
Continue Reading
Gary Presslaff Joins Ameriprise Financial Team In a significant move for the financial services landscape, mentor Gary Presslaff has officially joined the ranks of Ameriprise Financial, Inc. (NYSE: AMP). With four decades of industry experience, Presslaff brings a wealth of knowledge and expertise, bolstering the team at Monumental Financial Planning located in Washington...
Continue Reading
Royal Mint Commemorative Coin for Iron Maiden's 50th Anniversary The Royal Mint has recently unveiled an impressive commemorative coin that celebrates the remarkable 50-year journey of the legendary heavy metal band, Iron Maiden. This special release is part of The Royal Mint's Music Legends series, which has previously honored iconic musicians such as Queen, Elton John,...
Continue Reading